Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting

The AABB Annual Meeting is one of the largest scientific symposiums focused on the field on transfusion medicine. Scientists and clinicians from around the globe will be attending to learn about the latest developments in the industry, including the recently published final FDA guidance document on mitigating the risk of bacterial contamination in transfused platelet components.

“We are looking forward to the AABB meeting and sharing with the transfusion medicine community the latest clinical data supporting the use of INTERCEPT treated blood components. Between Cerus and our scientific collaborators, we will have 23 abstracts, including 6 oral presentations related to INTERCEPT,” said Dr. Richard Benjamin, Cerus’ Chief Medical Officer.

“We think the Swiss experience supporting the use of INTERCEPT treated platelets with a 7-day shelf-life in routine use in allogeneic stem cell transplant recipients over more than 5 years and data showing the absence of septic transfusions with pathogen-reduced platelets compared to culture-screened platelets that used a secondary rapid test on day 5 will be of particular interest at the conference given the final FDA guidance document,” continued Benjamin.

Company representatives from Cerus will be in the exhibition area at both #1133.

A full list of Cerus related abstracts can be viewed at https://intercept-usa.com/aabb2019. Information on Cerus’ industry workshop can be viewed at https://intercept-usa.com/images/AABB2019/Cerus_AABB_Workshop_Postcard__email.pdf.

Schedule of select oral presentations of interest and Cerus’ industry workshop (listed chronologically, all times in Central Daylight Time)

All meeting rooms are located in the Henry B. Gonzalez Convention Center.

Sunday, October 20, 2019

7:00 – 8:15 am - Cerus Corporation Industry Workshop: Are you ready for FDA’s Bacterial Contamination Guidance?, Room 214AB

4:45 - 5:00 pm - OA4-SN5-37: Pathogen Reduced Platelets Reduce Septic Transfusion Reactions Compared to Conventional Platelets – Despite Point of Release Testing, Room 302

Tuesday, October 22, 2019

11:30 – 11:45 am - OA3-TU3-25: Achieving 100% Pathogen Reduced Platelet Component Inventory with Production Optimization and Variable Dosing, Room 301

11:45 – 12:00 pm - OA4-TU3-25: Five Years of Routine Experience Using Amotosalen/UVA-Treated Platelets with Storage up to 7 Days, Room 301

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System, and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191018005108/en/